Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy

Journal of Clinical Microbiology

Volumn 43, Issue 1, 2005, Pages 186-191

  Takahashi, Masahiko ^a,b   Saito, Hidetsugu ^a   Higashimoto, Makiko ^b   Atsukawa, Kazuhiro ^a   Ishii, Hiromasa ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIGEN; INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KINETICS; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS CONCENTRATION; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIRAL LOAD;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 11844265960     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.1.186-191.2005     Document Type: Article

References (40)

1. Aoyagi, K., C. Ohue, K. Iida, T. Kimura, E. Tanaka, K. Kiyosawa, and S. Yagi. 1999. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J. Clin. Microbiol. 37:1802-1808.
2. Bouvier-Alias, M., K. Patel, H. Dahari, S. Beaucourt, P. Larderie, L. Blatt, C. Hezode, G. Picchio, D. Dhumeaox, A. U. Neumann, J. G. McHutchison, and J. M. Pawlotsky. 2002. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 36:211-218.
3. Brouwer, J. T., B. E. Hansen, H. G. Niesters, and S. W. Schalm. 1999. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J. Hepatol. 30:192-198.
4. Cheng, S. J., P. A. Bonis, J. Lau, N. Q. Pham, and J. B. Wong. 2001. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 33:231-240.
5. Choo, Q. L., K. H. Richman, J. H. Han, K. Berger, C. Lee, C. Dong, C. Gallegos, D. Coit, R. Medina-Selby, P. J. Barr, et al. 1991. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA 8:2451-2455.
6. Civeira, M. P., and J. Prieto. 1999. Early predictors of response to treatment in patients with chronic hepatitis C. J. Hepatol. 31(Suppl. 1):237-243.
7. Cividini, A., A. Cerino, A. Muzzi, M. Furione, C. Rebucci, L. Segagni, M. Gatti, V. Barnaba, and M. U. Mondelli. 2003. Kinetics and significance of serum hepatitis C virus core antigen in patients with acute hepatitis C. J. Clin. Microbiol. 41:2144-2146.
8. Cotler, S. J., J. E. Layden, A. U. Neumann, and D. M. Jensen. 2003. First phase hepatitis C viral kinetics in previous nonresponders patients. J. Viral Hepat. 10:43-49.
9. Davis, G. L., L. A. Baiart, E. R. Schiff, K. Lindsay, H. C. Bodenheimer, Jr., R. P. Perrillo, W. Carey, I. M. Jacobson, J. Payne, J. L. Dienstag, et al. for the Hepatitis Interventional Therapy Group. 1989. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 321:1501-1506.
10. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, and J. Albrecht for the International Hepatitis Interventional Therapy Group. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1493-1499.
11. Di Bisceglie, A. M., P. Martin, C. Kassianides, M. Lisker-Melman, L. Murray, J. Waggoner, Z. Goodman, S. M. Banks, and J. H. Hoofnagle. 1989. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321:1506-1510.
12. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
13. Gavier, B., M. A. Martinez-Gonzalez, J. I. Riezu-Boj, J. J. Lasarte, N. Garcia, M. P. Civeira, and J. Prieto. 1997. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 113:1647-1653.
14. Herrmann, E., A. U. Neumann, J. M. Schmidt, and S. Zeuzem. 2000. Hepatitis C virus kinetics. Antiviral Ther. 5:85-90.
15. Izopet, J., J. L. Payen, L. Alric, K. Sandres, J. P. Charlet, J. P. Vinel, M. Duffaut, J. P. Pascal, and J. Puel. 1998. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J. Med. Virol. 54:86-91.
16. Jessner, W., M. Gschwantler, P. Steindl-Munda, H. Hofer, T. Watkins-Riedel, F. Wrba, C. Mueller, A. Gangl, and P. Ferenci. 2001. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 358:1241-1242.
17. Kagawa, T., K. Hosoi, S. Takashimizu, K. Kawazoe, K. Mochizuki, M. Wasada, N. Nagata, J. Uchiyama, A. Nakano, Y. Nishizaki, N. Watanabe, and S. Matsuzaki. 1998. Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C. Am. J. Gastroenterol. 93:192-196.
18. Karino, Y., J. Toyota, M. Sugawara, K. Higashino, T. Sato, T. Ohmura, T. Suga, Y. Okuuchi, and T. Matsushima. 1997. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am. J. Gastroenterol. 92:61-65.
19. Kashiwakuma, T., A. Hasegawa, T. Kajita, A. Takata, H. Mori, Y. Ohta, E. Tanaka, K. Kiyosawa, T. Tanaka, S. Tanaka, N. Hattori, and M. Kohara. 1996. Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA). J. Immunol. Methods 190:79-89.
20. Lagging, L. M., C. E. Garcia, J. Westin, R. Wejstal, G. Norkrans, A. P. Dhillon, and M. Lindh. 2002. Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J. Clin. Microbiol. 40:4224-4229.
21. Lam, N. P., A. U. Neumann, D. R. Gretch, T. E. Wiley, A. S. Perelson, and T. J. Layden. 1997. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 26:226-231.
22. Layden, J. E., T. J. Layden, K. R. Reddy, R. S. Levy-Drummer, J. Poulakos, and A. U. Neumann. 2002. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J. Viral Hepat. 9:340-345.
23. Lee, W. M., K. R. Reddy, M. J. Tong, M. Black, D. J. van Leeuwen, F. B. Hollinger, K. D. Mullen, N. Pimstone, D. Albert, and S. Gardner for The Consensus Interferon Study Group. 1998. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 28:1411-1415.
24. Lunel, F., P. Veillon, I. Fouchard-Hubert, V. Loustaud-Ratti, A. Abergel, C. Silvain, H. Rifflet, A. Blanchi, X. Causse, Y. Bacq, and C. Payan. 2003. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen. J. Hepatol. 39:826-33.
25. Maynard, M., P. Pradat, P. Berthillon, G. Picchio, N. Voirin, M. Martinot, P. Marcellin, and C. Trepo. 2003. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy. J. Viral Hepat. 10:318-323.
26. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, and J. K. Albrecht for the Hepatitis Interventional Therapy Group. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
27. Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
28. Niederau, C., S. Lange, T. Heintges, A. Erhardt, M. Buschkamp, D. Hurter, M. Nawrocki, L. Kruska, F. Hensel, W. Petry, and D. Haussinger. 1998. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28:1687-1695.
29. Orito, E., M. Mizokami, K. Suzuki, K. Ohba, T. Ohno, M. Mori, K. Hayashi, K. Kato, S. Iino, and J. Y. Lau. 1995. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J. Med. Virol. 46:109-115.
30. Poynard, T., P. Bedossa, P. Opolon, and The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349:825-232.
31. Rebucci, C., A. Cerino, A. Cividini, L. Timo, M. Furione, and M. U. Mondelli. 2003. Monitoring response to antiviral therapy for patients with chronic hepatitis C virus infection by a core-antigen assay. J. Clin. Microbiol. 41:3881-3884.
32. Saito, H., H. Ebinuma, I. Satoh, S. Mivaguchi, S. Tada, N. Iwabuchi, N. Kumagai, K. Tsuchimoto, T. Morizane, and H. Ishii. 2000. Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J. Viral Hepat. 7:64-74.
33. Takahashi, K., H. Okamoto, S. Kishimoto, E. Munekata, K. Tachibana, Y. Akahane, H. Yoshizawa, and S. Mishiro. 1992. Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts. J. Gen. Virol. 73:667-672.
34. Tanaka, E., K. Kiyosawa, A. Matsumoto, T. Kashiwakuma, A. Hasegawa, H. Mori, O. Yanagihara, and Y. Ohta. 1996. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology 23:1330-1333.
35. Tanaka, T., J. Y. Lau, M. Mizokami, E. Orito, E. Tanaka, K. Kiyosawa, K. Yasui, Y. Ohta, A. Hasegawa, S. Tanaka, et al. 1995. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. J. Hepatol. 23:742-745.
36. Yoshida, H., Y. Arakawa, M. Sata, S. Nishiguchi, M. Yano, S. Fujiyama, G. Yamada, O. Yokosuka, Y. Shiratori, and M. Omata. 2002. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123:483-491.
37. Zaaijer, H. L., H. T. Cuypers, H. W. Reesink, I. N. Winkel, G. Gerken, and P. N. Lilie. 1993. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 341:722-724.
38. Zanetti, A. R., L. Romano, M. Brunetto, M. Colombo, G. Bellati, and C. Tackney. 2003. Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. J. Med. Virol. 70:27-30.
39. Zeuzem, S., J. H. Lee, A. Franke, B. Ruster, O. Prummer, G. Herrmann, and W. K. Roth. 1998. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 27:1149-1156.
40. Zeuzem, S., J. M. Schmidt, J. H. Lee, B. Ruster, and W. K. Roth. 1996. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 23:366-371.